Eindhoven, the Netherlands, August 2, 2022
Haermonics, a clinical-stage breakthrough medtech company, has successfully closed a 4.3 M Series-A financing round with an investment syndicate led by existing shareholder BOM, strategic partner Demcon and Stepping Stone (a fund managed by healthtech venture builder NLC), further including impact investor Invest-nl and a group of strategic private co-investors. Haermonics’ innovative and highly effective flush therapy – the Haermonics Pure™ therapy – demonstratively prevents post-operative cardiac surgery complications. Every day 250 patients die from postoperative heart surgery complications caused by residual blood and clots in the pericardial cavity. With this latest round of funding, such complications are closer to being a thing of the past.
This latest successful financing round will provide the necessary support to build the final product to CE mark requirements, in time for the planned 2024 launch. Having already demonstrated blood loss reduction and a dramatic drop in re-operations after cardiac surgery, Haermonics’ FLUID trial at 4 clinics will further prove the effectiveness of the Pure™ therapy with its investigational device, while collecting data necessary for the CE mark and FDA approval.
Initial response to this straight-forward but revolutionary treatment has been very positive.
Dr. Patrick Klein, Chair of Cardio Thoracic Surgery at St. Antonius (one of the participating hospitals) has nothing but praise for the invention and the results of the trial so far. “It’s extremely rare nowadays to be able to employ an intervention that is this simple, yet this effective. It’s nothing less than a potential game-changer.”
Wouter Markus, CEO and co-founder of Haermonics appreciates the highly relevant expertise the investors bring to the table. “We’re able to develop and bring something revolutionary to market because of the combined effort of our world-class group of investors. Mercedes Tuin (BOM) has been a big believer from the start and has been instrumental in fundraising. Then take Demcon’s experience in product development, NLC’s extensive network and VINC’s additional support in attracting investment and you see how the total team improves the quality of everything we do.”
Investment and partnerships will likely be important for a long time. While all the attention right now is on the life-saving market of cardiac surgery, Haermonics has no intention of stopping there. Their innovative invention to reduce blood and clotting complications is envisioned as a platform technology that could be employed in a variety of other surgical procedures. Markus underscores Haermonics’ vision of saving lives while saving costs, without extra burden on healthcare professionals. “We make patient care safer and less expensive while alleviating intensive care staff at the same time. Our innovation does not require a change in procedures and the final product will employ easy to use technology.
Alongside finishing their clinical trials, Haermonics will be looking to expand their current team with qualified medical device engineers, a product manager and an operations officer.
Haermonics is a clinical stage MedTech company developing innovative therapies to prevent post-operative (cardiac) surgery complications. When it comes to solving important, real-life medical problems, the Haermonics team brings discipline, creativity, and extensive testing to each and every elegant solution. We think the smartest way to solve a problem is to prevent it.
Haermonics has received financing from ZonMw and Kansen voor West, a regional EFRO grant. The company is co-financed by Rabobank and Braventure. For more information: www.haermonics.com
About BOM Brabant Ventures
BOM (the Brabant Development Agency) works together with businesses to create a strong, sustainable, and future-proof Brabant economy. BOM uses the Brabant Ventures label to focus, using knowledge and capital, on the accelerated and future-proof growth of ambitious Brabant startups and scaleups in the High-Tech Systems and Software, Agri-food, Life Sciences & Health, Maintenance, Supply Chain, and Bio-based Economy top industries. For more information: www.bom.nl
Demcon (1.000 employees) develops, produces and supplies technology and innovative, high-quality products. The company was created as a result of the passion of its founders for combining creativity and technical skills focused on solving complex issues for challenging technological and social problems. For more information: www.demcon.com
Invest-NL is an impact investor committed to businesses and projects that will make the Netherlands more sustainable and innovative. The company offers financing and consulting solutions to innovative companies. Being the National Promotional Institution (NPI) of the Netherlands Invest-NL partners with European investment institutions such as the European Investment Bank (EIB) and the European Investment Fund (EIF). For more information: www.invest-nl.nl
About Stepping Stone/NLC
NLC is Europe’s largest healthtech venture builder, aiming to bring more medical innovations to patients. Having been involved with Haermonics since the company was founded, they are now providing fresh capital to the venture via their stepping Stone Fund.
For more information: www.nlc.health
VINC – The Capital of Life Sciences
For more information: www.vincls.com
For further inquiries:
Wouter Markus, CEO
5616 LZ Eindhoven
T: +31 6 55 37 25 07